Evidence map›Paper›PMID 37198668›Full record

Trial reportCancer imaging : the official publication of the International Cancer Imaging Society2023

PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.

Alexander Brose, Kerstin Michalski, Juri Ruf, Marco Tosch, Susanne M Eschmann, Mathias Schreckenberger, Jochem König, Ursula Nestle, Matthias Miederer

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Cancer imaging : the official publication of the International Cancer Imaging Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Prognostic value of metabolic tumor volume on [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Trial
  2. Immuno-PET Imaging of EGFR withMolecular pharmaceutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Alexander BroseDepartment of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, University of Technology Dresden (TUD), Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. alex_brose@msn.com.ORCID http://orcid.org/0000-0001-8033-6855
Kerstin MichalskiDepartment of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Juri RufDepartment of Nuclear Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Marco ToschDepartment of Nuclear Medicine, Helios University Hospital Wuppertal, Wuppertal, Germany.
Susanne M EschmannDepartment of Nuclear Medicine, Marienhospital Stuttgart, Stuttgart, Germany.
Mathias SchreckenbergerDepartment of Nuclear Medicine, University Medical Center Mainz, Johannes Gutenberg-University Mainz, Mainz, Germany.
Jochem KönigInstitute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center Mainz, Johannes Gutenberg-University Mainz, Mainz, Germany.
Ursula NestleDepartment of Radiation Oncology, Kliniken Maria Hilf, Mönchengladbach, Germany.
Matthias MiedererDepartment of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, University of Technology Dresden (TUD), Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
German Cancer Research Center · DEJohannes Gutenberg University Mainz · DEUniversity of Freiburg · DEMarienhospital Stuttgart · DEUniversity Medical Center Freiburg · DEWitten/Herdecke University · DE

Funding

Deutsche Krebshilfe 70114389
6 · The paper itself

Abstract

backgroundCurrent studies indicate that fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography ([

methodsThis retrospective analysis comprises 114 PET/CT data sets of 82 patients from the PET-Plan multi-center study cohort who underwent [

resultsOverall interobserver agreement (IOA) of the visual assessment was moderate with a high difference between secure (ĸ = 0.66) and insecure (ĸ = 0.24) evaluations. Additional knowledge of the initial staging PET and radiotherapy delineation volumes improved the sensitivity (0.85 vs 0.92) but did not show significant impact on the specificity (0.86 vs 0.89). PET parameters SUVmax and SULpeak showed lower accuracy compared to the visual assessment, whereas threshold-based reading showed similar sensitivity (0.86) and higher specificity (0.97).

conclusionVisual assessment especially if associated with high reader certainty shows very high interobserver agreement and high accuracy that can be further increased by baseline PET/CT information. The implementation of a patient individual liver threshold value definition, similar to the threshold definition in PERCIST, offers a more standardized method matching the accuracy of experienced readers albeit not providing further improvement of accuracy.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyFluorodeoxyglucose F18HumansPositron-Emission TomographyPositron Emission Tomography Computed TomographyProspective StudiesRecurrenceRetrospective StudiesTomography, X-Ray ComputedFluorodeoxyglucose F18NSCLCOncologyPET/CTRelapse criteriaTumor recurrence

Identifiers

PMID37198668
PMCPMC10190104
OpenAlexW4377010572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.